Poster
HUmanized Genomic Ortholog (HUGO™) mouse models enable preclinical evaluation of human-targeted siRNA and antisense oligonucleotide therapies
Introducing the HUGO™ (HUmanized Genomic Ortholog) platform, which uses TurboKnockout™ technology to swap up to 500 kb of mouse genomic sequence for the human ortholog — promoters, exons, introns, and UTRs intact — and validates two such models with an approved siRNA and a splice-modulating ASO.

Overview
siRNA and ASO therapeutics depend on human transcript sequence and regulatory context, which cDNA-based rodent models cannot reproduce because they omit introns and native regulatory regions. The HUGO™ platform replaces up to 500 kb of murine locus with the corresponding human genomic ortholog, retaining promoters, exons, introns, and UTRs. In B6-hPCSK9 mice on a high-fat, high-cholesterol diet, a single subcutaneous dose of Inclisiran lowered serum LDL-C and significantly reduced serum and hepatic human PCSK9 by Day 19. In B6-huSMN2(SMA) mice, ICV ASO-10-27 raised brain SMN protein, preserved spinal anterior horn motor neurons, and extended median survival from 29 days to beyond 140 days.
Key Insights
HUGO™ mouse models replace the mouse locus with the full human genomic ortholog: introns, UTRs, and regulatory elements included, enabling preclinical evaluation of sequence-dependent siRNA and ASO therapeutics, as validated with Inclisiran and an SMN2 splice-modulating ASO.
- Genomic-scale humanization that preserves regulatory architecture. TurboKnockout™ enables replacement of up to 500 kb of the endogenous mouse locus with human genomic sequence, retaining promoters, exons, introns, and UTRs — the elements that cDNA-based models omit but on which siRNA and ASO recognition depends.
- Pharmacological validation with an approved siRNA. B6-hPCSK9 mice on a Western diet responded to a single 3 mg/kg subcutaneous dose of Inclisiran with reduced serum LDL-C and significantly decreased serum and hepatic human PCSK9 at Day 19, recapitulating the expected RNAi mechanism.
- Disease-modifying ASO response in an SMA model. In B6-huSMN2(SMA) mice, ICV-delivered ASO-10-27 increased brain SMN protein and anterior horn motor neuron counts, and shifted survival from a 29-day median (death by ~40 days) to first deaths only at 140 days, with markedly delayed tail and paw lesions.
Unlock Advanced Research Insights with Cyagen’s Resources
Explore an array of valuable resources tailored to enhance your preclinical research. Download mateirals meticulously crafted to provide advanced insights and methodologies. Elevate your research strategies with Cyagen's expertise.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
